Note: Direct Meds received an FDA marketing language warning in September 2025 that has been remediated
Drugs like semaglutide and tirzepatide are seeing a surge in demand
Abstract GLP-1 medicines, initially developed for blood glucose and weight control, improve outcomes in people with cardiovascular, kidney, liver, arthritis, and sleep apnea disorders, actions mediated in part through anti-inflammatory and metabolic pathways, with some benefits partly independent of the degree of weight loss achieved
K., Rosenstock, J., Wadden, T
"In addition, these results highlight the need for further research to elucidate potential mechanistic links between GLP-1 receptor agonist therapy, weight loss, and hair loss, and to identify patient level risk factors that may increase susceptibility to hair loss." It's worth pointing out that the medical records the researchers were dealing with were limited in terms of measuring the severity and duration of the hair loss, and whether or not it was reversible
doi:10.1001/jama.2023.19574
